BRISBANE, Australia, Dec 21 /PRNewswire/ -- Alchemia Limited advised that, further to its previous ASX announcement on 27 September 2006, it has now completed the satisfactory termination and settlement of its Research and Development Commercialisation and Distribution Agreement with Abraxis BioScience, Inc. formerly American Pharmaceutical Partners, Inc. (Abraxis), for synthetic heparin.
As indicated in its 27 September 2006 press release, Alchemia has repaid Abraxis the US$1.25 million convertible loan in full and Abraxis has returned to Alchemia all the heparin material in its possession together with other project related data.
Christopher Neal Alchemia Limited ABN 43 071 666 334 3 Hi-Tech Court, Brisbane Technology Park, Eight Mile Plains QLD 4113 PO Box 6242, Upper Mt Gravatt Qld 4122 Phone 61-7-3340 0200 Fax 61-7-3340 0222 E-mail: enquiries@alchemia.com.au World Wide Web: www.alchemia.com Chief Financial Officer and Company Secretary
Alchemia LimitedCONTACT: Christopher Neal, Chief Financial Officer and Company Secretaryof Alchemia Limited, +61-7-3340-0200, Fax 61-7-3340-0222,enquiries@alchemia.com.au
Web site: http://www.alchemia.com/
